The BCG–OPPI paper Winning in Indian Healthcare 2024 highlights India as a high-growth healthcare market, projected to become a $120B pharma hub by 2030. Strong GDP growth, FDI inflows, expanding insurance, digital infrastructure, and rising affluence drive demand. Global Pharma has invested heavily in trials, patient programs, and innovation, improving access and care. Yet challenges remain: fragmented payer systems, price controls, IPR disputes, and slow approvals. Policy reforms on patents, pricing, and drug reviews are creating a more predictable environment. Success will require local adaptation, partnerships, affordability strategies, and patient-centric programs.

Join for free to read